Devonian Health Group Inc. (CVE:GSD – Get Free Report) dropped 23.5% during mid-day trading on Saturday . The stock traded as low as C$0.09 and last traded at C$0.13. Approximately 119,000 shares were traded during mid-day trading, an increase of 588% from the average daily volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Stock Performance
The business has a 50-day moving average price of C$0.16 and a 200-day moving average price of C$0.17. The firm has a market capitalization of C$19.27 million, a price-to-earnings ratio of -4.64 and a beta of 0.67. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- The Risks of Owning Bonds
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- Transportation Stocks Investing
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Energy and Oil Stocks Explained
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
